^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD20-targeted antibody-drug conjugate

    Related drugs:
    Apply
    A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL. (NCT05395533)
    Phase 1
    Zhejiang Teruisi Pharmaceutical Inc.
    Recruiting
    Last update posted :
    10/25/2023
    Initiation :
    09/08/2020
    Primary completion :
    12/31/2023
    Completion :
    12/31/2024
    CD20
    |
    CD20 positive
    |
    TRS005
    Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim (NCT03057418)
    Phase 1
    Biointegrator LLC
    Completed
    Last update posted :
    05/23/2017
    Initiation :
    06/01/2013
    Primary completion :
    12/01/2016
    Completion :
    12/01/2016
    CD20
    |
    CD20 positive
    |
    Aurixim (rituximab conjugate)